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Steroid hormone receptors regulate gene expression, interacting with target DNA sequences but also
activating cytoplasmic signaling pathways. Using the human 11-hydroxysteroid dehydrogenase type 2 (11-
HSD2) gene as a model, we have investigated the contributions of both effects on a human progesterone-
responsive promoter in breast cancer cells. Chromatin immunoprecipitation has identified two different
mechanisms of hormone-induced progesterone receptor (PR) recruitment to the 11-HSD2 promoter: (i)
direct PR binding to DNA at the proximal promoter, abrogated when PR contains a mutated DNA binding
domain (DBD), and (ii) STAT5A (signal transducer and activator of transcription 5A)-mediated recruitment
of PR to an upstream distal region, impaired by AG490, a JAK/STAT pathway inhibitor. The JAK/STAT
inhibitor, as well as expression of dominant-negative STAT5A, impairs hormone induction of 11-HSD2. On
the other hand, the DBD-mutated PR fully supports 11-HSD2 expression. These results, along with data from
a deletion analysis, indicate that the distal region is crucial for hormone regulation of 11-HSD2. We show
active RNA polymerase II tracking from the distal region upon PR and STAT5A binding, concomitant with
synthesis of noncoding, hormone-dependent RNAs, suggesting that this region works as a hormone-dependent
transcriptional enhancer. In conclusion, coordination of PR transcriptional effects and cytoplasmic signaling
activation, in particular the JAK/STAT pathway, are critical in regulating progestin-induced endogenous
11-HSD2 gene expression in breast cancer cells. This is not unique to this promoter, as AG490 also alters the
expression of other progesterone-regulated genes.
Steroid hormone receptors (SHRs) are considered nuclear
transcription factors that, upon activation by binding with their
corresponding ligands, regulate the expression of different tar-
get genes. Ligand-activated SHRs act either by binding as
dimers to their hormone-responsive elements (HREs) at pro-
moters or by interaction with other DNA-bound factors. In
both cases, the process results in the recruitment of coregula-
tors, chromatin remodeling complexes, and the general tran-
scriptional machinery (7). However, SHRs also modulate gene
expression by activation of cytoplasmic signaling pathways
(nongenomic actions) (22).
The estrogen receptor (ER) binds to c-Src and to the phos-
phoinositol 3-kinase (PI3K) regulatory subunit, activating the
Src/Ras/Erk and PI3K/Akt pathways, respectively (15, 41).
These rapid effects triggered by hormones have been associ-
ated with their proliferative role. Ligand-activated progester-
one receptor (PR) activates the Src/Ras/Erk pathway indirectly
via an interaction with ER in the absence of estrogens (5),
although direct interaction and activation of c-Src by PR has
also been reported (11).
The relationship between SHRs’ direct transcriptional ef-
fects and those mediated by activation of cytoplasmic kinase
cascades in the hormone-inducible mouse mammary tumor
virus (MMTV) promoter was recently investigated (62). After
progesterone treatment, Erk and Msk1 are activated and re-
cruited with phosphorylated PR to the promoter, where his-
tone H3 is phosphorylated and acetylated locally. These H3
modifications seem to be a key switch for the exchange of a
repressive complex containing HP1 by coactivators, chroma-
tin remodeling complexes, and RNA polymerase II (RNAP
II). Thus, rapid kinase activation by progestin may participate
in induction of PR direct target genes by preparing the chro-
matin for transcription, indicating that both PR actions cross
talk to each other.
In breast cancer cells, progestin also induces activation of
the JAK/STAT (signal transducer and activator of transcrip-
tion) pathway and the subsequent phosphorylation of STAT
proteins (47). The activation of the JAK/STAT pathway is
initiated by cytokines or growth factors binding to their specific
membrane-associated receptor. Receptor dimerization leads
to JAK activation, which sequentially autophosphorylates and
phosphorylates the receptor and STAT proteins. STAT pro-
teins dimerize, translocate to the nucleus, and bind to DNA
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sequences at target promoters (18, 20, 28). The receptors in-
volved in JAK activation may be those with intrinsic Tyr kinase
activity (e.g., epidermal growth factor receptor) as well as
those receptors lacking intrinsic kinase activity but to which
JAKs are noncovalently associated (e.g., prolactin receptor).
Also, it has been reported that, in breast cancer cells, progestin
activates the JAK/STAT pathway by means of ligand-bound
PR activation of the Tyr kinase c-Src (47). Additionally, it has
been reported that progestin stimulates the association be-
tween PR and STAT proteins and their translocation to the
nucleus (47, 49), as happens with other SHRs (14, 54, 55, 67),
but the significance of this interaction in gene expression has
not been addressed in detail. Moreover, STAT5A and -B have
been implicated in the regulation of the Bcl-X gene by the
glucocorticoid and PRs (50, 64).
To further explore the effects of SHRs on endogenous
genes, we chose the human 11-hydroxysteroid dehydrogenase
type 2 (11-HSD2) gene as a model system, since it has been
identified in previous microarray studies as being among the
strongest progestin- and glucocorticoid-induced genes in
breast cancer cells (65). The 11-HSD2 gene codifies an en-
zyme involved in the metabolism of glucocorticoids, particu-
larly in the conversion of the active ligand cortisol to the
inactive agonist cortisone (48). Due to the inability of cortisone
to induce the antiproliferative effect of glucocorticoid receptor
activation, 11-HSD2 expression has been associated with cell
proliferation. In accordance with this, 11-HSD2 is overex-
pressed in many neoplasic tissues and cell lines compared to
that in their healthy, differentiated tissues (19, 27, 48).
The 11-HSD2 promoter spans 1.8 kb upstream of the
transcription start site (TSS) (1). However, transcription factor
binding sites have been mostly characterized in the 400 bp of
the proximal promoter and part of the first exon (44). The
cis-acting elements characterized include Sp1, IkB, and NF-1
binding sites (3, 37, 44). The mechanism by which steroid
hormones control 11-HSD2 promoter activity has not been
explored in detail. Therefore, our aims were to characterize
the promoter regions responsible for hormone responsiveness
and to analyze the signaling pathways involved in hormone
induction.
Here, we report that progestin regulates 11-HSD2 gene
expression in breast cancer cells by hormone-dependent PR
binding to proximal and distal regions of its promoter. PR
binding to the distal promoter region depends on the JAK/
STAT pathway activation by progestin and on the recruitment
of STAT5A to the same region, while PR recruitment to the
proximal promoter region involves DNA direct receptor bind-
ing. Interfering with JAK/STAT activation completely abro-
gates 11-HSD2 response to progestin. The distal region of the
11-HSD2 promoter is the main region responsible for the
hormone responsiveness of this promoter, acting as an entry
site for RNAP II, which then tracks to the main TSS in the
proximal promoter. These results provide new insights into the
role of rapid nongenomic signaling of steroid receptors in
mediating gene expression through activated signaling path-
ways coupling with transcription factors.
MATERIALS AND METHODS
Reagents. R5020 was purchased from PerkinElmer Life Sciences; RU486
(RU) and ovine prolactin were from Sigma. ICI182780 (ICI) was from Tocris,
and PD98059 (PD), Wortmannin (WM), and AG490 (AG) inhibitors were from
Calbiochem. The anti-11-HSD2 protein antibody was purchased from Binding
Site; anti-FLAG-tag antibody was from Sigma; anti-STAT5A was from Santa
Cruz; anti-phospho-STAT5A/B (Tyr694/6999), clone 8-5-2, was from Upstate;
anti-phospho-JAK2 (Tyr1007/1008) was from Cell Signaling; anti-polymerase II
(RNAP II) and phospho-polymerase II (RNAP II S5p) antibodies were from
Covance; anti-AcH4 and pS10-H3 antibodies were from Upstate; anti-
3MeK4-H3 and SRC-1 were from Abcam; anti-tubulin was from Sigma.
Cell lines, culturing conditions, and hormone treatment. T47D breast cancer
cells and T47D-MTVL cells (carrying one stably integrated copy of the luciferase
[Luc] reporter gene driven by the MMTV promoter [59]) were routinely grown
in Dulbecco’s modified Eagle’s medium and RPMI 1640 medium, respectively,
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml
penicillin, and 100 mg/ml streptomycin.
T47D-YV cells (PR-negative clonal derivative cell line of T47D [30, 53]) were
used to generate TYML cells (T47D-YV-derived cell lines with one integrated
copy of MMTV-Luc) expressing either the wild-type (WT) PR isoform B (PRB)
or PRB mutants (DNA binding domain [DBD] or AF2) from the retroviral
vector pRAV-Flag (36) (unpublished results). All T47D-YV-derived cell lines
were routinely grown in modified Eagle’s medium supplemented with 7% FBS,
2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
For the experiments, cells were plated in phenol red-free medium supple-
mented with 10% dextran-coated charcoal-treated FBS and, 24 h later, the
medium was replaced by fresh serum-free medium. After 2 days under serum-
free conditions, cells were treated with R5020 (10 nM) or ethanol for different
times at 37°C. Prolactin was used at 500 ng/ml. When indicated, RU (1 M) or
ICI (10 M) was added simultaneously, or PD (50 M), WM (0.1 M), or AG
(50 M) was added 1 h before hormone treatment.
Plasmids. The pGL3-1778 11Luc reporter vector was a gift from Lewis P.
Rubin (1). The entire promoter construct pGL3-1778117 11Luc was obtained
by adding 117 bp of exon 1, obtained by PCR amplification of human genomic
DNA with primers 368 (5-GTGTCCCGAACAAGCGTGAGTGGC-3) and
608 (5-TCTCACTTTCCCTCCAACACTCCC-3), followed by digestion of
the product with ApaI and NcoI. The unique restriction sites NcoI, AatII, and
BssHII were used to obtain the deletion constructs starting at positions 1551,
839, and 571, respectively. The deletion construct at 1345 was generated by
amplification from the pGL3-1778117 11Luc plasmid, with the oligonucleo-
tide 5-TTTGGTACCTCCCAGCCTCCCCTGAGATT-3, corresponding to the
nucleotides from 1345 to 1326, plus a KpnI restriction site, and the oligonu-
cleotide 5-CAGTGGAGGGTGGGGTGTCAG-3, corresponding to the nucle-
otides from 748 to 769, as forward and reverse primers, respectively. The
PCR product was cut with KpnI and AatII and then cloned into the KpnI and
AatII sites of the pGL3-839117 11Luc construct.
The vector pGL3-1778-1345 11Luc was generated by amplification from the
pGL3-1778117 11Luc plasmid, with the oligonucleotide 5-ATTTCTCTATC
GATAGGTACC-3, which includes the KpnI restriction sequence of the pGL3
reporter vector multiple cloning site, and the oligonucleotide 5-AAAGGTAC
CGCCAGACCCACC-3, corresponding to the nucleotides from 1345 to
1336, plus a KpnI restriction site added to perform the cloning, as forward and
reverse primers, respectively. The PCR product was digested with KpnI and then
cloned into the KpnI site of the pGL3 reporter vector. The vector pGL3-1778-
1345/368117 11Luc was generated by cloning the same PCR product into
the KpnI site of the pGL3-368117 11Luc construct.
pSG5-PRB and pSG5-PRA were gifts from Pierre Chambon (34).
pSTAT5A-WT and pSTAT5A*6 (STAT5A constitutively active [CA] mutant)
were kindly provided by Toshio Kitamura (4). pSTAT5A749 (STAT5A domi-
nant-negative [DN] mutant) was a gift from Fabrice Gouilleux (43).
Immunofluorescence. T47D cells were seeded onto coverslips in 35-mm dishes
at 1.2 	 105 cells/cm2 as described above for serum-free hormone treatment
experiments. After the treatment with ethanol or R5020, cells were washed, fixed
by incubation in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15
min at room temperature, and permeabilized by incubation in 0.2% Triton X-100
in PBS for 10 min at room temperature. After three 5-min rinses in PBS, the
coverslips were incubated for 1 h with 3% bovine serum albumin (BSA) in PBS
at room temperature to reduce nonspecific staining. To detect 11-HSD2 pro-
tein, cells were incubated with specific antibody against 11-HSD2 diluted
1:1,000 in 3% BSA in PBS for 1 h at room temperature. After several washes in
PBS, the coverslips were exposed to biotinylated-secondary anti-goat antibody
(Molecular Probes) diluted 1:200 in 3% BSA in PBS for 1 h at room tempera-
ture. Then, the coverslips were washed in PBS and exposed to streptavidin-
conjugated antibody Alexa 488 (Molecular Probes), diluted 1:1,000 in 3% BSA
in PBS for 1 h at room temperature. The coverslips were mounted on slides with
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VectaShield DAPI (4,6-diamidino-2-phenylindole) mounting medium (Vector
Laboratories) and subjected to a Leica DM IRBE inverted research microscope.
To detect phospho-JAK-2, cells were incubated with specific antibody diluted
1:500 in 3% BSA in PBS for 1 h at room temperature. After several washes in
PBS, coverslips were incubated for 1 h with Alexa Fluor 555-conjugated goat
anti-rabbit immunoglobulin G (IgG; Invitrogen), diluted 1:250 in 3% BSA in
PBS for 1 h at room temperature. Nuclei were stained with DAPI, and the
coverslips were mounted on slides with Mowiol mounting medium and subjected
to a Leica SPE confocal inverted microscope.
Immunoblotting. Cells treated as indicated above were lysed in Tris-HCl (pH
7.4; 25 mM), EDTA (1 mM), EGTA (1 mM), and sodium dodecyl sulfate (1%)
plus protease and phosphatase inhibitors. Cell lysates were obtained by centrif-
ugation, and protein concentration was determined by Micro bicinchoninic acid
protein assays (Pierce). Lysates were adjusted to equivalent protein concentra-
tions with lysis buffer, subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and analyzed by Western blotting using specific antibodies.
RNA extraction and RT-PCR. Total RNA was prepared by using Trizol re-
agent (Invitrogen) as described in the manufacturer’s instructions. The cDNA
was generated from 100 ng of total RNA by using the Superscript first-strand
synthesis system (Invitrogen). One microliter of cDNA was used as a template
for PCR. Indicated gene products were analyzed by PCR with specific oligonu-
cleotides, followed by visualization in agarose gel. When indicated, quantification
of gene products was performed by real-time PCR using LightCycler 480 Sybr
green I Master (Roche). Each value was corrected by the human GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) gene and expressed as relative
units. Gene-specific oligonucleotide sequences are available on request. Each
experiment was performed in duplicate, as were the following real-time PCR
quantifications (total n 
 4). Results for one experiment representative of at
least two experiments are shown.
Transfection assays. For transient transfections, 2 	 105 cells plated in 35-mm
plates were transfected with Lipofectamine 2000 (Invitrogen), following the
manufacturer’s instructions. A total amount of 3 g of reporter and expression
vectors was used per well. Six hours later, the medium was replaced by phenol
red-free medium with antibiotics. After 2 days under serum-free conditions, cells
were incubated with R5020 for 16 h. After incubation, cells were harvested in
lysis buffer (Promega) and the protein amount was determined by a Micro
bicinchoninic acid protein assay (Pierce). Lysates were adjusted to equivalent
protein concentrations with lysis buffer, and Luc activity was determined with a
Luc assay kit (Promega) according to the manufacturer’s instructions. For dele-
tion analysis of the 11-HSD2 promoter, the vectors expressing Luc under the
control of the different constructs of the promoter were transfected into T47D or
T47D-YV cells, together with empty pSG5, pSG5-PRB, or pSG5-PRA expres-
sion vectors. For expression analysis of the 11-HSD2 promoter under the
control of WT STAT5A or mutant STAT5A forms, 11Luc reporter constructs
were cotransfected in T47D-YV cells with a pSG5-PRB expression vector and
pSTAT5A-WT, pSTAT5A*6, or pSTAT5A749 expression vectors. Each exper-
iment was performed in duplicate, as were the following Luc measurements
(total n 
 4). Results for one experiment representative of at least two experi-
ments are shown.
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed
as described previously (56), using chromatin from TYML cells expressing Flag-
tagged WT PRB or, when indicated, PRB DBD or AF2 mutants, cultured and
treated as described previously. Chromatin was sonicated to an average fragment
size of 400 to 500 bp, routinely, in a Branson Sonifier. For the experiment whose
results are shown in Fig. 8C and D, fragments with an average size of 200 bp were
obtained using a Diagenode Bioruptor. Rabbit or mouse IgG (Sigma) was used
as a control for nonspecific interaction of DNA. In order to determine the linear
range of the amplification, different numbers of cycles and dilution series of input
DNA were used for PCR analysis of each amplicon. Input was prepared with
10% of the chromatin material used for an immunoprecipitation. Later, a 1:10
dilution of input material was performed before PCR amplification. The human
-globin gene amplicon was used as a loading control, detecting unspecific
binding of genomic DNA to beads or IgGs. PCR products were resolved in
agarose gel. Alternatively, quantification of gene products was performed by
real-time PCR using LightCycler 480 Sybr green I Master (Roche). Each value
was corrected by the level for the human actin gene and expressed as relative
units. Primer sequences and specific PCR conditions are available on request.
The numbers of PCR amplification cycles were as follows: 28 for amplicons A, B,
D, and G; 30 for amplicons C, E, F, H, I, and NucB; and 32 for -globin. Results
for one experiment representative of at least two experiments are shown.
In silico analysis. Screening for potential transcription factor binding sites was
performed by Web-based prediction of regulatory elements, using ConSite
(52) (http://www.phylofoot.org/consite) and Transfac (68) (http://www.gene
-regulation.com/pub/databases.html#transfac). Data on RNA maps discussed by
Kapranov et al. (32) were accessed through the National Center for
Biotechnology Information’s Gene Expression Omnibus (GEO; accession
number GSE7576) (http://www.ncbi.nlm.nih.gov/geo/).
Microarray data accession number. Microarray data are available at GEO
under accession number GSE9286 (http://www.ncbi.nlm.nih.gov/geo/index.cgi).
RESULTS
11-HSD2 transcription is induced by progestin in breast
cancer cells and depends on PR. To check the hormone re-
sponsiveness of the 11-HSD2 promoter in human breast can-
cer cells, serum-starved T47D cells were incubated with the
progestin R5020, and mRNA expression was analyzed by RT-
PCR (Fig. 1A). After 16 h of treatment, 11-HSD2 expression
was increased by R5020 treatment, and the induction was to-
tally abolished by RU incubation (Fig. 1A). This result indi-
cated that the promoter expression is specifically induced by
progestin through the activation of PR in T47D cells. 11-
HSD2 protein accumulation in response to R5020 treatment
was also detected with a specific antibody (Fig. 1B).
To analyze the kinetics of promoter activation by progestin,
11-HSD2 transcript accumulation was examined at different
time points after R5020 addition. A gradual increase of 11-
HSD2 transcription was observed, already evident at 30 min
and reaching nearly plateau levels after 6 h (Fig. 1C). Real-
time PCR quantification of 11-HSD2 cDNA repeatedly
showed 8- to 12-fold induction after 6 h of R5020 treatment
(see Fig. 4C and 5B as examples).
The distal 1778/1345 promoter region is required for
progesterone induction. In order to investigate the mechanism
underlying hormonal activation of 11-HSD2 transcription, we
first focused on defining the minimal promoter region required
for hormone response. Previous reports have defined the 11-
HSD2 promoter as the 1,778 bp preceding the TSS and part of
the first exon (1, 44). In silico analysis revealed several poten-
tial HRE half-sites along this promoter sequence (Fig. 2A).
To define the regions mediating induction by progestin, se-
rial deletion constructs of the human 11-HSD2 promoter
were fused to the Luc reporter and tested in transient trans-
fection experiments with the PR-negative clonal derivative
T47D-YV (30, 53), with and without expression vectors for
PRB or PR isoform A (PRA) (Fig. 2 and Table 1).
The entire 11-HSD2 promoter (1778/117) transfected
into T47D-YV cells was unsensitive to R5020 due to the lack
of endogenous PR isoforms. When the promoter construct was
cotransfected with a PRB expression vector, a robust response
to R5020 (up to 11-fold induction) was obtained (Fig. 2B).
Deletion of the 1/117 region, which contains several pre-
viously identified Sp1 binding sites (1), did not significantly
affect the hormone response. Deletion of the 1778/1551
region led to a partial reduction in R5020 induction, while
deletion of the 1778/839 region (or further deletions) com-
pletely abolished 11-HSD2 promoter activity (Fig. 2B). In a
separate experiment, deletion at1345 also showed a substan-
tial reduction of transcriptional response to hormone (Fig.
2C). Similar results were obtained when PRA was used instead
of PRB for cotransfection with promoter constructs into
T47D-YV, although the induction was slightly lower, indicat-
ing that PRA is also transcriptionally active on this gene and
acts through the same promoter region (Table 1).
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Similar experiments were performed with T47D cells to in-
vestigate the hormone responses of some of the 11-HSD2
promoter constructs in the context of endogenous PRB and
PRA levels (Table 1). Full-length promoter constructs re-
sponded to R5020 with a threefold induction. Deletions to
839 or further downstream lost this response. When T47D
cells were cotransfected with a PRB or PRA expression vector,
a strong hormone response (up to 13-fold) was observed, sim-
ilar to that of transfected T47D-YV (Table 1). In conclusion,
overexpression of any PR isoform improves the response ob-
tained by endogenous PR in transfection assays. Interestingly,
shorter promoter constructs (down to 368/117) retained a
significant hormone-dependent activity (threefold) in PRB-
overexpressing T47D cells, indicating that this proximal region
may also contain a weak but independent element responding
to hormone activation.
These results led us to conclude that the region between
1778 and 1345 encompasses the information required for
most of the promoter responsiveness to progestin in the con-
text of PR-expressing cells. Interestingly, deletion at 1551
retains a proportion of this capacity. Under receptor overex-
pression conditions, the proximal 368/117 region also
presents some hormone response in the context of reporter
constructs.
PR associates with two different regions of 11-HSD2 pro-
moter after hormone activation. In order to further character-
ize the regulation of 11-HSD2 gene expression by progester-
one, PR recruitment to the endogenous promoter was
investigated by ChIP. For this, we used a T47D-YV-derived
cell line containing an integrated copy of the progesterone-
responsive reporter MMTV-Luc (TYML cells), stably express-
ing a FLAG-tagged version of the WT PRB isoform (unpub-
lished results). Expression of tagged PRB in this cell line was
comparable to endogenous PRB expression in T47D cells
FIG. 1. 11-HSD2 promoter expression in T47D cells is induced by progestin and depends on the classical PR. (A) T47D cells were cultured
in phenol red-free medium under serum-free conditions for 48 h before the addition of R5020 (10 nM) and/or RU (1 M) or vehicle for 16 h.
Cells were harvested, and total RNA was extracted. The 11-HSD2 mRNA expression was analyzed by RT-PCR with specific primers. GAPDH
cDNA-specific primers were used as a control. PCR products were run on a 1.2% agarose gel and visualized with ethidium bromide. (B) Hormone-
induced accumulation of 11-HSD2 enzyme detected by immunofluorescence. T47D cells were cultured over coverslips in 10% FBS rich medium
or in serum-free, steroid-deprived medium for 48 h before the addition of R5020 (10 nM) or ethanol (EtOH) for 24 h. Then, the cells were fixed,
impermeabilized, and incubated with anti-11-HSD2 antibody, followed by incubation with biotinylated secondary antibody and then streptavidin-
conjugated Alexa 488 and, finally, DAPI, to stain nucleic acids (as described in Materials and Methods). (Lower panels) For a negative control,
T47D cells cultured in rich medium were analyzed as previously described in the absence of the primary antibody. (C) T47D cells, cultured as
described for panel A, were untreated (0) or treated with R5020 (10 nM) for the times indicated. 11-HSD2 expression was analyzed as described
for panel A, and GAPDH expression was used as a control.
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(data not shown). PR recruitment in response to R5020 treat-
ment was analyzed at 5, 10, and 30 min using an anti-FLAG-tag
antibody, and the 1778/117 promoter region was exten-
sively covered with eight PCR amplicons (Fig. 3A).
In accordance with the involvement of the 1778/1345
region described above, ChIP analysis showed that, in response
to hormone activation, PR was recruited to this distal region,
represented by amplicons A and B (Fig. 3B). Similarly, upon
hormone addition, PR was recruited to the proximal 368/1
promoter region (amplicons G and H) (Fig. 3B). However, the
promoter deletion analysis showed limited induction by R5020
in this region (Table 1). PR recruitment was not observed in
the middle amplicons or in a coding region (423/620). As
controls, in the same experiment we confirmed PR recruitment
to the well-studied MMTV promoter after progestin treatment
and no recruitment to the -globin gene. These results dem-
onstrate that R5020 treatment induces rapid and stable (up to
30 min) PR recruitment to the distal and the proximal regions
of the 11-HSD2 promoter. This finding was confirmed for
T47D cells expressing endogenous PR by means of a PR-
specific antibody (data not shown).
Mutations in the DBD of the receptor affect PR recruitment
to the proximal promoter but not endogenous 11-HSD2 ex-
pression. We next investigated the mechanisms involved in
hormone-dependent PR recruitment to the two 11-HSD2
promoter regions. The classical mode of action of PR on gene
expression involves direct binding of PR to the HREs in the
target promoter. This is the case of the MMTV promoter
which contains five HREs in a region covered by a regulatory
nucleosome (16). The first zinc finger of the receptor DBD is
responsible for the direct contact with DNA via its so-called P
box (8). Point mutations in this zinc finger have been shown to
interfere with PR binding to target promoters (9, 57). We have
TABLE 1. Summary of 11-HSD2 promoter deletion analysis
results obtained with T47D-YV and T47D cellsa
Cell type and
overexpressed isoform
11-HSD2
promoter region Fold induction Range
T47D-YV 1778/117 1.51 0.10
PRB 1778/117 11.41 0.21
1778/1 10.38 0.34
1551/117 8.66 0.02
839/117 1.26 0.01
571/117 1.10 0.01
368/117 1.12 0.02
PRA 1778/117 8.07 1.54
1778/1 9.25 0.44
1551/117 6.57 0.03
839/117 1.35 0.03
571/117 1.13 0.03
368/117 1.07 0.01
T47D 1778/117 3.15 0.11
1778/1 2.92 0.07
839/117 1.66 0.20
571/117 1.53 0.10
368/117 1.53 0.07
PRB 1778/117 12.24 0.77
1778/1 13.43 0.51
1551/117 5.49 0.29
839/117 2.70 0.79
571/117 3.28 0.17
368/117 3.05 0.36
PRA 1778/117 8.68 0.21
1778/1 7.95 0.51
839/117 1.38 0.48
571/117 2.09 0.06
368/117 1.59 0.26
a The average induction levels and ranges of Luc activity for hormone/vehicle
from two independent experiments performed in duplicate are shown.
FIG. 2. An 11-HSD2 promoter region upstream of nucleotide
1345 is necessary for progesterone-induced activation. (A) Human
11-HSD2 promoter region structure. Arrows indicate the positions of
NF1 and Sp1 binding sites. The vertical bars along the 11-HSD2
promoter region indicate the positions of potential progesterone re-
ceptor elements predicted by computational analysis with ConSite and
Transfac software. The deletion endpoints used in the deletion analysis
are indicated. (B, C) Analysis of promoter deletion constructs driving
Luc reporter expression. Indicated constructs (1778, 1551, 839,
571, and 368 in panel B; 1778, 1551, and 1345 in panel C)
were transfected together with a PRB expression vector into T47D-YV
cells. After transfection, cells were serum starved for 48 h and then
treated with ethanol (EtOH) or R5020 (10 nM) for 16 h and Luc
activity was measured. For normalization, equal amounts of extracted
protein of each sample were used. Data of a representative experiment
performed in duplicate, with each sample analyzed in duplicate, are
expressed as mean numbers of Luc arbitrary units, and error bars
represent the data ranges. Induction in response to hormone com-
pared to the level for ethanol is shown for each construct.
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FIG. 3. PR binds to two different regions of the 11-HSD2 promoter after hormone activation. (A) Schematic representation of the 11-HSD2
promoter region with the locations of amplicons for ChIP analysis as well as the location and sequence of the potential STAT5A binding site as
predicted by ConSite and Transfac software. (B) TYML cells (T47D-YV cell line carrying an integrated copy of the progesterone reporter
MMTV-Luc), expressing FLAG-tagged WT PRB, were cultured as described for Fig. 1A, untreated (0) or treated with R5020 (10 nM) for 5, 10,
or 30 min, harvested, and used for ChIP experiments with anti-FLAG antibody. The precipitated DNA fragments were subjected to PCR with
primers for the indicated 11-HSD2 promoter regions or the -globin gene as a control. The MMTV nucleosome B region was also amplified to
detect PR recruitment as a control for the experiment. Amplification of input DNA (representing 1% of immunoprecipitated material) is shown
for comparison. PCR products were run in a 1.2% agarose gel and visualized with ethidium bromide.
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used a TYML-derived cell line expressing FLAG-tagged PRB
mutated at residues G584, S585, and V589 (PRB-mDBD) of
the P box of the zinc finger (unpublished results) to study
whether PR recruitment to the 11-HSD2 promoter involves
direct DNA binding. As we expected, PRB-mDBD recruit-
ment to the MMTV promoter at the integrated MMTV-Luc
transgene was impaired (Fig. 4A; also see Fig. 8C). Accord-
ingly, endogenous MMTV-Luc transcriptional activation was
abrogated by the DBD mutation (Fig. 4B).
ChIP analysis of progestin-induced PR recruitment showed
that mutation in the DBD of PRB did not affect its recruitment
to the distal 11-HSD2 promoter region upon hormone treat-
ment but completely abrogated recruitment to the proximal
region (Fig. 4A; also see Fig. 8C). These results indicated that
direct contact of PRB with DNA is required for association
with the proximal region only.
To explore whether the inability of PRB-mDBD to bind to
the proximal 11-HSD2 promoter affects promoter activation,
we checked endogenous 11-HSD2 mRNA expression after
R5020 treatment in this cell line by RT-PCR. In contrast to
MMTV expression, 11-HSD2 expression in TYML cells ex-
pressing PRB-mDBD was activated similarly to that in WT-
PRB-expressing cells (Fig. 4B and C). This is in accordance
with the deletion analysis, indicating that PR binding to the
proximal region is not essential for the hormonal induction of
11-HSD2 gene expression, whereas the distal region plays an
essential role.
Inhibition of JAK/STAT pathway activation compromises
hormone induction of 11-HSD2. We next explored the mech-
anism by which PR is recruited to the distal promoter region
and induces its activation. Steroid receptors can also be re-
cruited to promoters indirectly, through interaction with other
transcriptional factors. A sequence analysis of the distal region
of the 11-HSD2 promoter revealed the presence of a putative
STAT5A binding site at nucleotides 1654/1646 (Fig. 3A),
close to the consensus STAT5A sequence TTC/ANNNG/TAA
(18). STAT transcription factors bind to target promoters to
alter gene expression upon phosphorylation by JAK-2, dimer-
ization, and translocation to the nucleus (28, 29). JAK-2 is
activated by a number of membrane-associated, phosphoty-
rosine-dependent receptors. A recent work with breast cancer
cells has described that progestin also induces activation of the
JAK/STAT pathway, STAT3 phosphorylation, association of
PR with STAT3, and translocation to the nucleus (47). Other
reports have shown progestin-induced nuclear translocation of
STAT5A in T47D cells (49) or progestin-PR-dependent re-
cruitment of STAT5A to the -casein promoter (13). None-
theless, these reports have failed to detect progestin-stimu-
lated tyrosine phosphorylation of total cellular STAT5A and
suggested that only a small proportion of total STAT5A may
get phosphorylated and may intervene in specific promoter
recruitment (13). In agreement with this, we have been able to
slightly detect phosphorylation of STAT5A shortly after R5020
treatment of serum-starved T47D cells by immunoblotting with
a specific antibody (Fig. 5A). Prolactin was a stronger inducer
of STAT5A phosphorylation. R5020-induced phosphorylation
was blocked by preincubation with the specific JAK-2 inhibitor
AG. Similarly, JAK-2 phosphorylation was detected by immu-
nofluorescence shortly after R5020 treatment of T47D cells
and blocked by AG preincubation (data not shown).
FIG. 4. Effect of PR mutations at the DBD on progesterone-in-
duced 11-HSD2 promoter activity. (A) TYML cells expressing
FLAG-tagged WT PRB or mutant DBD PRB (PRB-mDBD), cultured
as described for Fig. 1A, were untreated (0) or treated with R5020 (10
nM) for 5 or 10 min, harvested, and used for ChIP experiments with
anti-FLAG tag (FLAG) antibody. The precipitated DNA fragments
were subjected to PCR analysis with specific primers corresponding to
the distal or proximal 11-HSD2 promoter region, with MMTV nu-
cleosome B and the -globin gene as a control. (B) TYML cells
expressing WT PRB or PRB-mDBD, cultured as described for Fig. 1A,
were untreated (0) or treated with R5020 (10 nM) for 9 or 12 h. Cells
were harvested, and total RNA was extracted. The 11-HSD2 and
MMTV-Luc mRNA expression levels were analyzed by RT-PCR with
specific primers. GAPDH cDNA-specific primers were used as a con-
trol. PCR products were run on a 1.2% agarose gel and visualized with
ethidium bromide. (C) TYML cells expressing WT PRB or PRB-
mDBD, cultured as described for Fig. 1A, were untreated (0) or
treated with R5020 (10 nM) for 2, 6, or 10 h. Cells were then harvested,
and total RNA was extracted. 11-HSD2 mRNA expression was an-
alyzed by RT and real-time PCR with specific primers. GAPDH ex-
pression was measured for normalization. Data of a representative
experiment performed in duplicate, with each sample analyzed in du-
plicate, are expressed as mean numbers of 11-HSD2/GAPDH rela-
tive units, and error bars represent the data ranges.
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In order to test the possibility that STAT5A could be in-
volved in PR recruitment to the distal promoter region and
hormone-dependent 11-HSD2 expression, we explored
whether the JAK/STAT pathway was involved in 11-HSD2
activation by R5020. First, we investigated by RT-PCR the
effect of the specific JAK-2 inhibitor (AG at 50 M) on en-
dogenous 11-HSD2 mRNA accumulation upon hormone
treatment (Fig. 5B). Normal induction of 11-HSD2 expres-
sion was abrogated in the presence of the JAK inhibitor. The
integrated MMTV-Luc reporter, analyzed for comparison, was
normally activated after addition of R5020 to AG-treated cells
(Fig. 5B). These results indicate that JAK/STAT pathway ac-
tivation has an important and specific role in 11-HSD2 hor-
mone-induced expression.
Other signaling pathways have been reported to be rapidly
activated by progestin and to mediate their effects, including
cell proliferation of breast cancer cells (5, 11, 42, 51). This
includes PI3K and mitogen-activated protein kinase (MAPK)
pathways. Hormonal activation of the MMTV promoter de-
pends not only on PR interaction with several HREs but also
on the ER/c-Src/Ras/Erk pathway (62). Inhibitors of ER or
MEK1 interfere with MMTV activation. In order to test
whether these pathways are also essential for 11-HSD2 acti-
vation by progestin, we measured 11-HSD2 transcript accu-
FIG. 5. JAK/STAT pathway activation is involved in the hormonal induction of 11-HSD2 gene expression. (A) T47D cells were cultured in
phenol red-free medium under serum-free conditions for 72 h prior to the addition of 10 nM R5020 for 5, 10, or 15 min or 500 ng/ml prolactin
(PRL) for 10 min. When indicated, 1 h before hormonal induction, cells were treated with 50 M AG. Cell lysates were analyzed by Western
blotting with antibodies against phosphorylated STAT5A (Tyr694/699) and tubulin. (B) T47D cells, cultured as described for Fig. 1A, were treated
with R5020 (10 nM) for 0, 2, or 6 h. When indicated, AG (50 M) was added 1 h before hormone addition. Cells were harvested, and total RNA
was extracted. (Upper panel) 11-HSD2 and MMTV-Luc mRNA expression levels were analyzed by RT-PCR with specific primers. GAPDH
cDNA-specific primers were used as a control. PCR products were run on a 1.2% agarose gel and visualized with ethidium bromide. (Lower panel)
11-HSD2 mRNA expression was analyzed by RT and real-time PCR with specific primers. GAPDH cDNA-specific primers were used as a
control. The values represent the means and ranges of a representative experiment performed in duplicate, with each sample analyzed in duplicate,
expressed as numbers of 11-HSD2/GAPDH relative units. (C) Involvement of MAPK and PI3K pathways in hormone activation of 11-HSD2.
T47D cells, cultured as described for Fig. 1A, were untreated (0) or treated with R5020 (10 nM) for 2, 6, or 12 h. When indicated, PD (50 M),
WM (0.1 M), or ICI (10 M) was added 1 h before hormone induction. Cells were harvested, total RNA was prepared, and cDNA was generated
by RT. 11-HSD2 expression was analyzed by real-time PCR with specific primers. To normalize the data, GAPDH expression was used as a
control. The values represent the means and standard deviations of two experiments performed in duplicate, expressed as numbers of 11-HSD2/
GAPDH relative units. Asterisks denote significant differences (P  0.05) between treated (PD or WM) and untreated (only R5020) data sets, as
analyzed by Student’s t test. (D) T47D-YV cells cotransfected with WT pSG5-PRB and reporter 11-HSD2-Luc vectors were treated with R5020
(10 nM) for 16 h, and Luc activity was determined. When indicated, cells were treated with AG (50 M) 1 h before hormone addition. For
normalization, equal amounts of cellular extract of each sample were used. The values represent the mean numbers of arbitrary Luc units and
ranges of a representative experiment performed in duplicate. EtOH, ethanol. (E) Expression of 11-HSD2 reporter construct in the presence of
a Pro cluster PR mutant. T47D-YV cells cotransfected with WT pSG5-PRB or a Pro cluster mutant and reporter 11-HSD2-Luc vectors were
treated with R5020 (10 nM) for 16 h, and Luc activity was determined. For normalization, equal amounts of cellular extract of each sample were
used. The values represent the mean numbers of arbitrary Luc units and ranges of a representative experiment performed in duplicate.
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mulation after R5020 treatment alone or in the presence of an
ER antagonist (ICI), an MEK1 inhibitor (PD), or an inhibi-
tor of the PI3K pathway (WM). We observed small and tran-
sient effects with the inhibitors of MEK1 and PI3K on 11-
HSD2 induction and no effect with ICI (Fig. 5C). This
indicates that the activation of the ER/c-Src/Ras/Erk and
PI3K pathways is not by any means as important as the acti-
vation of JAK/STAT on 11-HSD2 expression, in contrast to
what has been reported for the MMTV promoter.
The effect of AG treatment on the hormone response of
a transfected 11-HSD2-Luc full-length construct was also
tested. Induction of Luc activity by 16 h of R5020 treatment
was abolished when cells were pretreated with AG for 1 h
(Fig. 5D).
JAK/STAT pathway activation by progestin involves c-Src
tyrosine kinase activation that then phosphorylates JAK-2
(47). PR directly contacts the c-Src SH3 domain through a
proline (Pro) cluster located at the inhibition function domain
of PR. A PR mutant on this Pro cluster abrogates this contact
and c-Src activation by progestin (11). We tested the induction
of the 11-HSD2-Luc construct in the presence of WT and Pro
cluster mutant (PR-mPro) PR-expressing vectors. The mutant
showed reduced activation of the 11-HSD2 promoter upon
progestin treatment (Fig. 5E). In parallel, MMTV-Luc induc-
tion was unaffected by the Pro cluster defect (data not shown).
Alternatively, in certain contexts c-Src is activated by ER
upon progestin treatment, through an interaction of PR with
ER (5). When we performed the experiment using a PR
mutant unable to interact with ER (PR-ERID I), progestin
induction of 11-HSD2-Luc was not affected (data not shown).
Taken together, the data confirm the involvement of JAK/
STAT pathway activation in progestin-induced 11-HSD2 ex-
pression.
JAK-2 inhibition compromises hormone induction of other
progesterone target genes. We next considered whether hor-
mone induction of other target genes is dependent on activa-
tion of the JAK/STAT pathway. With this purpose, we used a
breast cancer microarray platform containing 826 cDNA
clones (C. Ballare´, B. Min˜ana, and M. Beato, unpublished
results). Analysis of T47D cells treated with R5020 or vehicle
for 6 h and pretreated or not with AG for 1 h pinpointed a
number of genes regulated by progestin and affected by JAK/
STAT pathway inhibition (see the supplemental material).
Nineteen genes showed 2-fold inductions in response to
R5020 compared to the vehicle level in the absence of AG.
Among them, only two (Dusp1 and Il6st) showed more than
50% reduction in hormone response in the presence of the
inhibitor, and six genes had lost 30 to 50% of the response
(Dnah1, Jun, Hmgb3, Muc2L, Cyr61, and Atf3). Figure 6A and
B show examples of progestin-regulated genes affected or not,
respectively, by AG pretreatment, validated by RT/real-time
PCR. Progestin activation of Dusp1, Il6st, Jun, Hmgb3, and
Stat5A genes was affected by AG to an extent comparable to
that of 11-HSD2 inhibition. On the other hand, hormone
FIG. 6. Involvement of JAK/STAT pathway activation in progestin-induced gene expression. T47D cells, cultured as described for Fig. 1A, were
treated for 6 h with R5020 (10 nM) or ethanol (Et), and when indicated, AG was added 1 h before hormone. Cells were harvested, and total RNA
was extracted. Expression of the genes indicated was analyzed by RT and real-time PCR with specific primers. GAPDH cDNA-specific primers
were used as a control. The values represent the means and ranges of a representative experiment performed in duplicate, expressed as numbers
of specific gene/GAPDH relative units. Inductions in response to hormone are indicated.
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responsiveness of Ccnd1, Ccng2, Myc, Pcaf, Sos1, and Sap30
was not significantly affected, despite the fact that basal ex-
pression levels are, in some cases, altered by this JAK/STAT
inhibitor.
STAT5A is functionally important for hormone-dependent
11-HSD2 expression and exerts its action through the distal
promoter region. The involvement of the JAK/STAT pathway
in 11-HSD2 expression suggested that the predicted STAT5A
site found at the distal region could be important. In order to
analyze the functional involvement of STAT5A on progestin-
induced 11-HSD2 gene expression, we took advantage of
existing DN or CA STAT5A mutants. The DN form consists of
a deletion in the C-terminal transactivation domain that still
binds to DNA upon activation but is unable to interact with
many coregulators or to induce transcription (43). The CA
form contains mutations that mimic stable Tyr phosphoryla-
tion, leading to nuclear accumulation, DNA binding, and
transactivation activity (4). T47D-YV cells were cotransfected
with the full-length 11-HSD2-Luc reporter construct, PRB
expression vector, and WT, CA, or DN STAT5A expression
vectors, and the response to R5020 was measured (Fig. 7A).
11-HSD2-driven Luc activity depended on PRB expression
and hormone. Overexpression of WT and CA STAT5A mod-
estly enhanced the hormone response of the promoter com-
pared to that of endogenous STAT5A. Importantly, DN
STAT5A impaired the response to the progestin, confirming
that STAT5A plays an important role in the hormone activa-
tion of the 11-HSD2 promoter. In addition, the DN form also
reduced the basal promoter activity (Fig. 7A).
In a different experiment, we compared the effects of WT
and DN STAT5A on the full-length (1778/117) and1551/
117 (lacking the identified well-conserved STAT5A binding
site) 11-HSD2-Luc constructs. Interestingly, both constructs
were similarly affected by the STAT5A forms (Fig. 7B). The
fact that activity of the 1551 deletion is also enhanced by
WT STAT5A and abolished by DN STAT5A indicates that
STAT5A exerts its function not only through the predicted
STAT5A binding site but also through an unknown sequence
located downstream.
To test whether the reduced activity of the proximal pro-
moter constructs (down to 368/117) identified in transient
transfection experiments on T47D cells overexpressing PRB
(Table 1) depended on STAT5A activation, we performed a
similar experiment, cotransfecting or not cotransfecting DN
STAT5A (Fig. 7C). As expected, DN STAT5A affected the
hormone induction of the long constructs but not the shortest
ones that show the same reduced hormone response irrespec-
tive of STAT5A. This indicates that residual activation medi-
ated through the proximal promoter region is not dependent
FIG. 7. Expression of DN STAT5A affects the hormone activation of the 11-HSD2 promoter. (A) T47D-YV cells were cotransfected when
indicated with 1 g of 11-HSD2-Luc (1778/117) reporter vector, 1 g of pSG5-PRB, and 1 g of WT STAT5A, CA STAT5A, or DN
STAT5A. Afterwards, cells were treated with ethanol (EtOH) or R5020 (10 nM) for 16 h and Luc activity was measured. For normalization, equal
amounts of cellular extract of each sample were used. The values represent the mean numbers of arbitrary Luc units and ranges of a representative
experiment performed in duplicate. Induction in response to hormone is shown for each construct. (B, C) T47D-YV (B) or T47D (C) cells
cotransfected with 1 g of the indicated 11-HSD2 promoter constructs, 1 g of pSG5-PRB, and 1 g of plasmid expressing WT STAT5A or DN
STAT5A were treated with ethanol or R5020 (10 nM) for 16 h, and Luc activity was measured. Induction in response to hormone is shown for
each construct. The values represent the means and ranges of a representative experiment performed in duplicate.
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on STAT5A, in accordance with the finding that PRB binds
there through its DBD (Fig. 4A).
STAT5A is recruited to the distal region of the 11-HSD2
promoter in response to progestin. We next investigated
STAT5A recruitment to the 11-HSD2 promoter in TYML
cells expressing FLAG-tagged WT PRB, using ChIP experi-
ments. Upon hormone addition, STAT5A rapidly associated to
11-HSD2 distal promoter regions A and B (Fig. 8A). Irre-
spective of the hormone, no STAT5A bound the proximal or
middle region of the 11-HSD2 promoter. As a control, we
confirmed in the same experiment that PR is recruited to both
distal and proximal promoter regions (Fig. 8A). These results
showed that STAT5A is recruited to the distal region of the
11-HSD2 promoter in a hormone-dependent manner and
with kinetics similar to that of PR. We expected recruitment to
the predicted STAT5A binding site (amplicon A), but associ-
ation was also found with amplicon B, in agreement with the
previous data showing that DN STAT5A also affected the
1551 but not the 1345 deletion.
Hormone-dependent PR recruitment to the distal promoter
depends on JAK/STAT pathway activation. In order to test the
possibility that STAT5A hormone-dependent recruitment to
its binding site at the distal 11-HSD2 promoter region could
be involved in PR recruitment, we investigated the effect of
blocking JAK/STAT pathway activation with AG on receptor
recruitment. As expected, the inhibitor abrogated the observed
STAT5A recruitment to the distal region (Fig. 8B). Signifi-
cantly, in the presence of the JAK/STAT inhibitor, PR recruit-
ment in response to R5020 to the distal 11-HSD2 promoter
region was diminished, while recruitment to the proximal re-
gion was unaltered (Fig. 8B). As a control, we tested if inter-
fering with JAK/STAT activation would affect PR recruitment
to another hormone-regulated promoter. ChIP experiments
using MMTV nucleosome B-specific primers showed that PR
is normally recruited in the presence of AG (Fig. 8B).
Because a residual fraction of PR associated with the distal
promoter region in the presence of AG and consequently in
the absence of STAT5A recruitment (Fig. 8B), we investigated
whether this depended on direct interaction with DNA. When
the AG effect in the cell line expressing PRB-mDBD was
investigated, PR recruitment to the distal region (amplicons A
and B) was found to be completely abrogated. This indicates
that direct interaction of PR with DNA also plays some role in
this region, although STAT5A-mediated recruitment seems to
be the main mechanism (Fig. 8C, upper panel, compare lanes
4 to 6 with 10 to 12; real-time PCR quantification of amplicon
A is shown in Fig. 8D). Interestingly, STAT5A recruitment was
slightly reduced in the context of PRB-mDBD. All in all, this
suggests a cross talk between the two mechanisms of PR re-
cruitment converging into the distal region. STAT5A might be
the driving force behind PR recruitment, but then, this might
be stabilized by direct contacts of PR with DNA. A conforma-
tional change or chromatin remodeling might facilitate PR-
DNA contacts.
To further investigate the potential involvement of PR bind-
ing to the distal 11-HSD2 promoter region, evidenced in vivo
only when the JAK/STAT pathway is blocked, we combined
PRB-mDBD and DN STAT5A expression in Luc reporter
transfection experiments (Fig. 8E). In this context, PRB-
mDBD was not able to fully support the hormone response of
1778 and 1551 deletions, and combination of PRB-mDBD
with DN STAT5A completely abrogated promoter expression.
This suggests that both mechanisms, STAT5A-mediated and
direct interaction of PRB with DNA, play roles in the context
of transiently transfected 11-HSD2 promoter constructs, this
effect being mediated by a region located between 1551/
1345. The difference with the endogenous situation could be
that progesterone response elements (PREs) are likely more
exposed in the poorly chromatinized transfected templates.
Later on, we noted that the negative effect of mDBD could
also be observed when using the construct containing only the
distal region (1778/1345) driving Luc expression (see below
and Fig. 10C). Hormone induction was 2.7 times lower in
PRB-mDBD-expressing cells than in WT PRB (data not
shown). This experiment confirmed that functional putative
HREs in transient reporter constructs are within the distal
region, not provided by the proximal region.
PR/STAT5A cooperation for transcriptional activation of
11-HSD2. We have shown that 5 min after hormone addition,
PR and STAT5A are recruited to the distal 11-HSD2 pro-
moter region in a process that depends on JAK/STAT pathway
activation and that PR is also recruited to the proximal region,
requiring an intact DBD and implying PR binding to HREs.
We have further studied recruitment of transcription coregu-
lators and the changes in posttranslational modifications at
relevant histone residues. SRC-1 is a known coactivator of PR
FIG. 8. STAT5A and PR recruitment to the distal region depends on the JAK/STAT pathway. (A) TYML cells expressing FLAG-tagged WT
PRB were cultured as described for Fig. 1A, untreated (0) or treated with R5020 (10 nM) for 5 or 10 min, harvested, and used for ChIP experiments
using anti-STAT5A (STAT5A; middle panel) or anti-FLAG tag (right panel) antibodies. The precipitated DNA fragments were subjected to PCR
analysis with primers corresponding to the indicated 11-HSD2 promoter regions and the -globin gene. Input material (1%) is shown for
comparison. PCR products were run in a 1.2% agarose gel and visualized with ethidium bromide. (B) TYML cells expressing FLAG-tagged WT
PRB, cultured as described for Fig. 1A, were untreated (0) or treated with R5020 (10 nM) for 5 or 10 min, harvested, and used for ChIP
experiments with anti-STAT5A or anti-FLAG-tag antibodies. When indicated, cells were treated with AG (50 M) 1 h before hormone addition.
The precipitated DNA fragments were subjected to PCR analysis with specific primers corresponding to the distal and proximal 11-HSD2
promoter regions or MMTV nucleosome B and the -globin gene as a control. PCR products were run in a 1.2% agarose gel and visualized with
ethidium bromide. (C) ChIP experiment as in panel B from TYML cells expressing FLAG-tagged WT PRB or mutant DBD PRB (PRB-mDBD),
combined with AG (50 M). Here, the average chromatin fragment size was 200 bp (see Materials and Methods). (D) Real-time PCR
quantification of ChIP samples from panel C for distal amplicon A, performed in duplicate and normalized to actin gene amplification levels. The
values represent the means and data ranges. (E) T47D-YV cells cotransfected with 1 g of the 11-HSD2 1778 or 1551 promoter construct,
1 g of WT or PRB-mDBD, and 1 g of DN STAT5A when indicated were treated with ethanol (EtOH) or R5020 (10 nM) for 16 h, and Luc
activity was measured. Where indicated, 1 h of AG pretreatment was performed. Induction in response to hormone is shown for each construct.
The values represent the means and ranges of a representative experiment performed in duplicate.
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and STAT proteins with intrinsic histone acetyltransferase ac-
tivity and the ability to recruit additional histone acetyltrans-
ferases. Ten minutes after hormone addition, we found SRC-1
only at the distal region (Fig. 9A).
In order to explore whether SRC-1 recruitment was medi-
ated by PR or by STAT5A, we have used a TYML cell line
stably expressing a mutant PRB with a single amino acid ex-
change, E911A, at activation function 2 (PRB-mAF2) (25), as
AF2 is involved in coactivator recruitment (24, 38). The AF2
mutant impairs progestin response of MMTV in comparison to
the WT, despite normal recruitment of the mutated receptor
(data not shown). In contrast, the 11-HSD2 promoter is nor-
mally activated by the AF2 mutant (Fig. 9B). These results
suggest that coactivators such as SRC-1 are being recruited by
STAT5A, and PR is not contributing with its transactivation
functions.
Histone H3 phosphorylation at Ser10 (H3S10p) has been
associated with immediate-early gene activation by diverse
stimuli and with MMTV induction by R5020 (58, 62). We have
also observed phosphorylation of H3S10 upon hormone addi-
tion, localized to the two regions where PR is recruited (Fig.
9A). Mutation at DBD that abrogates PR recruitment to the
proximal region also abolished H3 Ser10 phosphorylation in
this region without affecting the distal region (Fig. 9A, right
panel).
We conclude that at the 11-HSD2 promoter, whereas an
H3S10 kinase is recruited by PR, coactivators such as SRC-1
are recruited solely by activated STAT5A.
RNAP II binds the distal region and tracks to the proximal
promoter. Binding of PR to two distant promoter regions of
the 11-HSD2 promoter could cause or reflect the formation
of a chromatin loop, bringing factors recruited by the PR-
STA5A association to the basal transcriptional machinery that
may initiate mRNA synthesis at the TSS. Against this loop
formation hypothesis is the fact that some factors (mainly
STAT5A) are not detected at the proximal region. To further
clarify the mechanism by which PR-STAT5A binding to the
distal region activates transcription about 1.6 kb downstream,
we performed ChIP to detect RNAP II. Surprisingly, RNAP II
was found to associate after 5 min of hormone treatment not
only to the proximal region but also to the distal and middle
regions (Fig. 9A). In order to check whether RNAP II is in its
active conformation along the 11-HSD2 promoter upon hor-
mone treatment, we used the H14 RNAP II antibody, specif-
ically detecting the phosphorylated form at Ser5 of its carboxyl-
terminal domain (45). This antibody indicated that RNAP II
FIG. 9. Coactivator recruitment and histone modifications at the 11-HSD2 promoter. (A) TYML cells expressing FLAG-tagged WT PRB,
cultured as described for Fig. 1A, were untreated (0) or treated with R5020 (10 nM) for 5 or 10 min, harvested, and used for ChIP experiments
with anti-FLAG tag (FLAG), STAT5A, SRC-1, H3S10p, and RNAP II antibodies. The precipitated DNA fragments were subjected to PCR
analysis with specific primers corresponding to the indicated 11-HSD2 promoter regions or MMTV nucleosome B and the -globin gene as a
control. For the right panel, ChIP with H3S10p antibody was performed on chromatin extracted from TYML cells expressing FLAG-tagged WT
PRB or PRB-mDBD, untreated or treated with R5020. (B) TYML cells expressing WT PRB or PRB-mAF2, cultured as described for Fig. 1A,
were untreated (0) or treated with R5020 (10 nM) for 2, 6, or 10 h. Cells were harvested, and total RNA was extracted. (Left) 11-HSD2 and
MMTV-Luc mRNA expression levels were analyzed by RT-PCR with specific primers. GAPDH cDNA-specific primers were used as a control.
PCR products were run on a 1.2% agarose gel and visualized with ethidium bromide. (Right) 11-HSD2 mRNA expression was analyzed by RT
and real-time PCR with specific primers. GAPDH cDNA-specific primers were used as a control. The values represent the means and ranges of
a representative experiment performed in duplicate, expressed as numbers of 11-HSD2/GAPDH relative units.
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engaged in, at least, preinitiation or initiation is already
present at the distal region and all along the promoter shortly
after hormone addition (Fig. 10A). Moreover, cells expressing
the PR DBD mutant show equivalent loadings of active RNAP
II to the proximal region, where PR-mDBD cannot be re-
cruited (Fig. 4A), indicating that PR is not involved in recruit-
ing the polymerase to the proximal region (Fig. 10A, right
panel).
FIG. 10. The distal region works as a hormone-responsive RNAP II entry site from where RNA synthesis occurs and enhances 11-HSD2
expression. (A) TYML cells expressing WT FLAG-tagged PRB, cultured as described for Fig. 1A, were untreated (0) or treated with R5020 (10
nM) for 5 or 10 min, harvested, and used for ChIP experiments with anti-FLAG tag (FLAG) and phospho(Ser5)-RNAP II (RNAP II S5p)
antibodies. The precipitated DNA fragments were subjected to PCR analysis with specific primers corresponding to the indicated 11-HSD2
promoter regions or MMTV nucleosome B and the -globin gene as a control. On the right panel, anti-phospho-RNAP II ChIP was performed
on chromatin extracted from TYML cells expressing FLAG-tagged WT PRB or PRB-mDBD, untreated or treated with R5020. (B) TYML cells
expressing FLAG-tagged WT PRB, cultured as described for Fig. 1A, were treated with ethanol or R5020 (10 nM) for 6 h. When indicated, cells
were pretreated with AG (50 M). Cells were harvested, total RNA was prepared, and cDNA was generated by RT using oligo(dT). RNA synthesis
was analyzed using primers that specifically amplified the 11-HSD2 promoter distal region and the proximal region and primers located in exon
3 and exon 4 (RT oligos). GAPDH-specific primers were used as a control. (C) T47D-YV cells cotransfected with 1.5 g of WT pSG5-PRB
expression vector, 1.5 g of the indicated 11-HSD2 deletion constructs was treated with ethanol (EtOH) or R5020 (10 nM) for 16 h, and Luc
activity was measured. For normalization, equal amounts of cellular extract of each sample were used. The values represent the mean numbers
of arbitrary Luc units and ranges of a representative experiment performed in duplicate. Inductions in response to hormone are indicated.
(D) TYML cells expressing FLAG-tagged WT PRB, cultured as described for Fig. 1A, were treated with EtOH or R5020 (10 nM) for 6 h. Then,
cells were harvested, total RNA was prepared, and cDNA was generated by RT using gene-specific sense primers at positions 1936 and 1778
upstream of the TSS. The presence of antisense RNA upstream of the TSS was analyzed using PCR primers at positions 1936/1779 (preA) and
1778/1596 (distal A) that specifically amplified the promoter region.
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These results indicate that a processing polymerase is loaded
at the distal region, coinciding with PR-STAT5A recruitment
upon hormone treatment, and probably tracks toward the
proximal promoter and initiation site. In order to test the
possibility that RNA is being synthesized upstream of the TSS
of 11-HSD2 identified in several tissues (2), we have per-
formed RT-PCR with oligonucleotide pairs covering the distal
and proximal promoter regions on T47D cells treated or not
with hormone and AG. Hormone-dependent, AG-sensitive
transcription is detected upstream of the reported TSS (Fig.
10B).
Our deletion analysis described above indicated that the
distal region was required for most of the hormone response of
the 11-HSD2 promoter and the proximal region retained
little responsiveness. Further constructs were prepared to ex-
plore the possibility that the distal region acted as a polymer-
ase entry site and were cotransfected with PRB into T47D cells
(Fig. 10C). First, an internal deletion, 1345/368, showed
the same hormone response as the full-length promoter, indi-
cating that the sequences between the distal and proximal
regions are devoid of regulatory elements, and the distance
between distal and proximal regions is not relevant. Notewor-
thy is the fact that the distal 1778/1345 region alone also
conserved full capacity to drive expression of the reporter gene
and was normally induced by hormone (Fig. 10C, upper panel).
This could indicate that this region, in fact, contained a pro-
moter, but data could also fit with the presence of a transcrip-
tional enhancer. Gene activation is a property of enhancers,
which are defined by their ability to direct high-level expression
of linked genes in transient transfection assays. Enhancer func-
tion includes not only long-distance but also orientation-inde-
pendent transcriptional activation. In order to test whether the
distal region acts as an enhancer or is a promoter by itself, we
inverted this region in the two previously reported constructs
and analyzed their hormone responses (Fig. 10C, lower panel).
The inverted constructs were as active on Luc expression as the
sense constructs, confirming that the distal region is not a
promoter by itself but an entry site for the transcriptional
machinery, probably at multiple, weakly defined sites, that then
tracks in the two directions.
In order to test whether antisense transcription occurred
from RNAP II entry sites at the endogenous promoter region,
we performed RT reactions with specific sense oligonucleo-
tides matching positions 1936 and 1778 upstream of the
TSS, followed by PCR amplification with specific oligonucleo-
tide pairs covering several promoter regions (Fig. 10D). RNA
extracted from T47D cells treated or not with R5020 for 6 h
was used. Amplification was obtained from the hormone-
treated cells, indicating that, concomitant with STAT5A, PR,
and RNAP II recruitment, transcripts covering the promoter
region were synthesized not only from the positive strand (Fig.
10B and data not shown) but also from the negative strand
(Fig. 10D).
In conclusion, our data show that the distal region works as
an enhancer, where STAT5A and PR recruitment brings the
transcriptional machinery that generates upstream RNAs co-
expressed with the main 11-HSD2 transcript. This high den-
sity of RNAP II tracks along the promoter and may initiate
11-HSD2 expression at the reported start site.
DISCUSSION
The aim of this work was to investigate the mechanisms
involved in gene expression activation by progesterone and
whether the two modes of action of the hormone receptor (i.e.,
acting as a transcription factor and interacting with cytoplasmic
signaling pathways) converge to regulate target promoters.
The MMTV promoter contained in its 5 long terminal repeat
has been extensively studied and has become the model for
progesterone- and glucocorticoid-induced gene expression in
human breast cancer cell lines (17, 63). Using this model, we
have recently contributed to connecting the rapid signaling
activation by progesterone with its transcriptional effect (62).
In this work, we have explored the activation of the endoge-
nous 11-HSD2 promoter, one of the strongest progestin and
glucocorticoid-induced genes in breast cancer cells, in order to
extend the understanding of the hormone receptors’ function.
In summary, our results show that PR is recruited to two
different regions of the 11-HSD2 promoter shortly after pro-
gestin treatment of serum-starved breast cancer cells. Recruit-
ment to a distal region is essential for promoter response and
involves JAK/STAT pathway activation and STAT5A pro-
moter binding. PR association with a proximal region involves
direct interaction with DNA, but this is not required for 11-
HSD2 gene expression upon hormone treatment.
JAK/STAT pathway activation by progestin is required for
11-HSD2 gene expression. We found that progestin activa-
tion of the JAK/STAT pathway plays an essential role in PR
recruitment to the promoter, again suggesting that the direct
transcriptional action of the receptor requires earlier events
initiated by the ability of the ligand-bound receptor to interact
with and activate cytoplasmic kinases engaged in intracellular
signaling. We investigated the participation of the JAK/STAT
pathway in hormone-induced 11-HSD2 expression after iden-
tifying a putative STAT5A binding site in the distal promoter
region. The JAK/STAT pathway induction by progestin leads
to STAT5A activation and corecruitment together with PR to
the distal enhancer region, which we have shown to be the
relevant region of the promoter for hormone response. Inter-
fering with JAK/STAT activation with AG blocks hormonal
induction of 11-HSD2 expression, STAT5A recruitment, and
PR association with the enhancer. However, none of this oc-
curred in the case of the MMTV promoter, indicating that
JAK/STAT activation by progestin is involved in 11-HSD2
but not in MMTV activation.
On the other hand, STAT5A activation is not sufficient, as
CA STAT5A is unable to increase 11-HSD2 expression in the
absence of hormone. This fact indicates that PR also has a
transcriptional role, presumably in the recruitment of histone-
modifying enzymes or chromatin-remodeling complexes. In ac-
cordance with this, prolactin, a strong inducer of JAK/STAT
activation and STA5A phosphorylation (as shown by phospho-
immunoblotting) does not activate the expression of 11-
HSD2 (data not shown).
Activation of the JAK/STAT pathway by progestin requires
c-Src tyrosine kinase activation (47). It has been proposed that
c-Src activation by progestin either occurs by direct contact
between a Pro cluster at the PR inhibition function domain
and the SH3 domain of c-Src (11) or is mediated by an inter-
action between the ER-interacting domains (ERIDs) of PR
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and the ligand-binding domain of ER, which then interacts
with the SH2 domain of c-Src (5, 42). Deletion of PR ERIDs
abrogates progestin activation of Erk and induction of an in-
tegrated MMTV promoter in T47D cells (5, 62). Progestin
induction of the transfected 11-HSD2-Luc construct, shown
to depend also on JAK/STAT pathway activation, was reduced
when a PR mutant on the Pro cluster was coexpressed. In the
presence of an ERID I-deleted PR, hormone induction was
normal. This supports the involvement of direct c-Src activa-
tion by PR on JAK and STAT5A activation and 11-HSD2
induction. Nonetheless, we cannot rule out a hypothetical in-
volvement of the ERIDs and PR-ER interaction in another
step of the induction process, if the promoter was immersed in
chromatin. In this vein, an ERID I-deleted PR supports
MMTV activation when the promoter is transiently trans-
fected, but not in chromatin, due to the role of the receptor in
the PR/ER/c-Src/Ras/Erk/Msk pathway (5, 62).
We used the JAK inhibitor AG to test whether the JAK/
STAT pathway activation was required for the hormone re-
sponse of other progestin target genes and found that only a
small proportion of R5020-responsive genes decreased their
response. This indicates that, although 11-HSD2 is not a
unique case, this pathway is not generally involved in proges-
tin-induced gene expression in breast cancer cells. Interest-
ingly, the hormone responses of some genes relevant to growth
control, such as Jun and Stat5A, are affected by the JAK/STAT
inhibitor. Interestingly, the JAK/STAT pathway activation may
be of relevance for breast cancer progression, as blockage of
STAT3 activation by a DN form resulted in inhibition of in vivo
breast tumor growth in an immunocompetent mouse model
(47).
Although our data suggest the JAK/STAT pathway activa-
tion by progestin to be involved in the induction of specific
promoters, detection of progestin-stimulated tyrosine phos-
phorylation of total cellular STAT5A by immunoblotting with
different available Pho-STAT5 antibodies was challenging
(Fig. 5A). This supports the hypothesis that progestin might
stimulate the phosphorylation of a small fraction of cellular
STAT5A and that phospho-STAT5A would be recruited to
specific promoters, including -casein (13) and 11-HSD2.
Involvement of other cytoplasmatic signaling pathways in
11-HSD2 expression. Other signaling pathways have been
reported to be rapidly activated by progestin and mediate their
effects, including cell proliferation of breast cancer cells (6, 22).
Hormonal activation of the MMTV promoter depends not
only on PR interaction with several HREs but also on the
hormone-activated ER/c-Src/Ras/Erk pathway (62). Inhibi-
tors of ER, MEK1, or Msk1 interfere with MMTV activation.
The PI3K pathway has also been reported to be activated by
hormone treatment. In particular, ligand-bound ER interacts
with the regulatory subunit of PI3K (p85) and activates the
PI3K/Akt/Ras/Erk pathway (15). By using specific inhibitors,
we have described a minor participation of MAPK (MEK1)
and PI3K in endogenous 11-HSD2 induction. These or other
pathways may participate in activating the kinases responsible
for phosphorylation of PR or other transcription factors in-
volved. For the MMTV, MAPK activation was involved in PR
phosphorylation, Msk1 activation, and H3 Ser10 phosphoryla-
tion at the promoter, and this was essential for promoter in-
duction (62). In 11-HSD2, this process seems to be unes-
sential attending at the low effect of MEK1 inhibition.
Nonetheless, we have also observed histone H3 S10 phosphor-
ylation concomitant to PR recruitment at the 11-HSD2 pro-
moter upon hormone addition. We therefore cannot discard
the possibility that Msk1 and H3 Ser10 phosphorylation could
also play an important role in 11-HSD2 expression, via a
signaling pathway other than MAPK. Further experiments are
required to fully understand the involvement of these proges-
tin-activated signaling pathways.
PR binds to two separate regions of the 11-HSD2 pro-
moter, but only binding to the distal enhancer depends on
STAT5A and is functionally relevant. We have found that PR
is recruited to two different regions of the 11-HSD2 promoter
as early as 5 min after hormone addition. PR recruitment to
the distal region was monitored with PCR amplicons covering
nucleotide positions 1778 to 1362, whereas PR association
with the proximal region was detected with amplicons covering
positions 336 to 6. PR recruitment to the distal region
occurred in parallel to STAT5A recruitment. Interfering with
JAK/STAT pathway activation impaired PR recruitment, indi-
cating that STAT5A binding to its binding site may bring PR to
the distal region. Direct association of PR with DNA at this
region was discarded for two reasons. First, a DBD mutant of
PR associated with the distal region similarly to WT PR upon
hormone treatment. Second, cells expressing this DBD mutant
induced endogenous 11-HSD2 gene expression normally. On
the other hand, PR recruitment to the proximal promoter
region depended on an intact DBD and was unaffected by
inhibition of the JAK/STAT pathway, suggesting that this re-
gion does not contribute significantly to the hormone response
of endogenous 11-HSD2.
In agreement with this, the deletion analysis of the promoter
with Luc reporter constructs showed that the proximal region
is hormone unresponsive. It retains minor hormone respon-
siveness only when PRB is transiently overexpressed in PRA/
PRB-expressing T47D cells. In contrast, the distal region is
strictly required for strong hormone response. Interestingly,
deletion at the intermediate 1551 position partially affected
induction, indicating that regulatory elements at the two sides
of this position may contribute to the transcriptional hormone
response. Coexpression of a DN form of STAT5A greatly
impaired reporter gene activity not only from the full-length
promoter but also from the 1551 construct, indicating that
STAT5A binding may not be limited only to the 1654/1646
site, where a canonical STAT5A binding site was predicted.
Additional cryptic STAT5A binding sites may exist after posi-
tion 1551. This is in accordance with our ChIP data showing
the STAT5A recruitment observed when an amplicon covering
positions 1542 to 1362 was used. We discard the notion
that this is due to the sizes of sonicated chromatin fragments
since, for the experiment shown in Fig. 8C, fragments had an
average size of 200 bp (data not shown). It also explains why,
with JAK/STAT activation being so crucial for 11-HSD2 ex-
pression, the 1551 construct retains considerable hormone
responsiveness.
Expression of DN STAT5A also showed that residual acti-
vation mediated through the proximal promoter region is not
dependent on STAT5A. This is in agreement with the findings
that PRB binds there through its DBD, that no STAT5A was
detected, and that PRB binding is insensitive to AG addition.
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Further analysis of promoter reporter constructs revealed
that the distal region is not only required for progestin-induced
promoter expression but also sufficient in the absence of the
proximal region in the context of transiently transfected tem-
plates. This was unexpected, as we assumed that this distal
region worked as an enhancer of the basal promoter located at
the proximal region and could indicate that the distal region
may have full promoter activity by itself. Alternatively, it has
been previously reported that enhancers may direct high-level
expression of linked reporter genes in transient transfection
assays. A prostate-specific antigen (PSA) reporter construct
containing only the enhancer was as active to androgens as the
full-length promoter (66). Also, the HS2 enhancer of the
-globin locus control region initiates synthesis of noncoding
RNAs (nc-RNAs) autonomously, independent of a cis-linked
promoter (40). The human growth hormone promoter is acti-
vated by a distal locus control region which creates a domain of
bidirectional noncoding transcription (26).
Given that enhancers may drive orientation-independent
transcriptional activation by loading RNA polymerases at mul-
tiple sites that then track in the two directions and that pro-
moters work in only one orientation, we constructed reporter
constructs containing the 11-HSD2 distal region in the anti-
sense direction with respect to the Luc gene. The results
showed that the distal region was equally active to drive hor-
mone-dependent expression of the reporter when placed in the
antisense direction, suggesting that it was acting as an en-
hancer instead of as a promoter.
In the absence of STAT5A, residual PR binds through DBD
to the distal region. As already mentioned, expression of a
DBD mutant of PR did not impair receptor and STAT5A
recruitment to the distal region. In the presence of the JAK/
STAT inhibitor AG, STAT5A was not recruited, but a minor
proportion of PR still associated to the distal region. Combin-
ing AG with the DBD mutant showed that in the absence of
STAT5A recruitment, there was some DBD-dependent asso-
ciation of PR with the distal promoter. This indicates that the
distal promoter region may contain potential PR binding sites
(HREs) that are not used when STAT5A can be activated to
recruit PR. Again, normal induction of endogenous 11-HSD2
in the presence of the PR DBD mutant supported this model.
On the other hand, analysis of transiently transfected 11-
HSD2 reporter constructs demonstrated that hormone re-
sponse was lower when PR-mDBD was coexpressed than with
WT PR. We speculate that this might be due to the poor
chromatinization of the transfected promoter, which might
leave potential HREs exposed, allowing direct binding of PR
to DNA and contributing to the hormonal response observed.
The remaining activity of the constructs seems to be due to
STAT5A-mediated PR recruitment, as combining PR-mDBD
with DN STAT5A completely abrogates their activation. This
effect was also seen with the 1551 deletion, indicating that
PR and STAT5A may contact the 1551/1345 region. In-
volvement of the putative STAT5A binding site identified in
1778/1551 (amplicon A) comes only from ChIP data at this
point.
Given these data, we can talk about convergence of two
mechanisms for PR recruitment to the 11-HSD2 promoter
distal region, mediated by STAT5A-contacting DNA and di-
rect association of PR with HREs. The first one seems to be
the principal driving force behind PR transcriptional activity,
and the second is apparent only when STAT5A activation is
impaired or in transiently transfected templates. We cannot
discard the possibility of a cross talk between the two mecha-
nisms of PR recruitment converging to the distal region. PR
might be recruited principally by STAT5A, but then, this might
be stabilized by direct contacts of PR with DNA. A conforma-
tional change or a chromatin remodeling may also facilitate the
PR-DNA contacts. Although we have proven that PR is also
recruited to HREs at the proximal promoter, we have not
found this to be functionally important. Further identification
and mutagenesis of participating HREs will help clarify
whether PR binding to DNA plays any as-yet-unrecognized
role.
RNAP II is recruited to the enhancer region and tracks
across the promoter, producing upstream RNAs. As early as 5
min after hormone addition to serum-free cultured cells, both
PR and STAT5A got recruited to the distal enhancer region of
the 11-HSD2 promoter and only PR to the proximal region.
Concomitantly, RNAP II showed association with all tested
regions of the promoter and the coding region. ChIP using an
antibody against phosphorylated RNAP II indicated that the
initially recruited enzyme was activated at Ser5 a few minutes
later, coinciding with other changes occurring at the promoter.
Histone H4 became acetylated, and H3 methylated at Lys4
along the promoter (data not shown). In contrast, H3 was
phosphorylated at Ser10 only in the regions where PR was
recruited. This resembles the recently described situation with
the MMTV promoter where a PR/Erk/Msk complex is re-
cruited to the regulatory nucleosome upon hormone stimula-
tion and phosphorylates H3S10 locally to start a chromatin-
remodeling cascade that facilitates transcription factor loading
and leads to transcription initiation (62). Accordingly, a mu-
tation at DBD that abrogated PR recruitment to the proximal
region showed no H3 Ser10 phosphorylation in this region
without affection of the distal region. SRC-1, a known STAT
and PR coactivator, is recruited only to the distal region, prob-
ably reflecting the fact that it is the PR-associated complex
recruited to the distal region that is functionally important.
The inability of PR binding to the proximal region to recruit
SRC-1 may explain why this PR interaction is not required for
functional response. It might also reflect an inappropriate re-
ceptor conformation due to promoter context effects, allosteric
effects of DNA sequence and architecture (39), or the reported
inability of PR binding to a single PRE to efficiently recruit
SRC-1 or a full complement of transcription factors (60). No
palindromic PRE and only few PRE half-sites are predicted at
the proximal 11-HSD2 promoter region (data not shown).
Several models for explaining how a distal enhancer com-
municates with a proximal promoter have been proposed:
looping, scanning, tracking, and linking (10, 12, 35, 46). Several
observations lead us to discard a pure looping mechanism.
Active RNAP II is observed not only in the distal and proximal
regions but also in the middle region, indicating that some sort
of scanning or tracking may take place. In addition, some
factors are only found at the distal region (STAT5A and SRC-
1). PR would be the hypothetical candidate for the establish-
ment of a loop, as it has contacts with the two distant regions,
but in that case, PR-mDBD would interfere with loop forma-
tion and affect gene activation, something we do not observe.
3846 SUBTIL-RODRI´GUEZ ET AL. MOL. CELL. BIOL.
Moreover, cells expressing PR-mDBD show equivalent load-
ing of active RNAP II to the proximal region, indicating that
the enzyme may be tracking from the entry site in the distal
region.
From our data, we can speculate that RNAP II and some
chromatin-modifying enzymes (responsible for H4 acetylation
and H3K4 methylation) track (or scan) along the promoter
without carrying PR, STAT5A, or SRC-1. We have also tested
whether active RNAP II tracking involves RNA synthesis. We
have detected by RT-PCR the synthesis of hormone-depen-
dent, AG-sensitive, polyadenylated upstream transcripts cov-
ering the distal and proximal regions. Moreover, by using spe-
cific sense and antisense RT oligonucleotides, we have
detected bidirectional, hormone-dependent transcripts cover-
ing the promoter region. This is in accordance with the ob-
served capacity of the distal promoter region to direct ex-
pression of a reporter gene in response to hormones,
independently of directionality, in transfection experiments. It
will be interesting to further explore the length and coverage of
the upstream RNA molecules generated as well as whether
they play a specific role in transcription initiation from the
promoter or if they are a by-product of RNAP II activity.
Based on previous reports, we speculate that RNA polymerase
tracking may involve upstream nc-RNA synthesis (in one or
the two directions), maybe from poorly defined start sites at
the enhancer, to deliver the machinery to the proximal pro-
moter, where transcription starts consistently at a defined 1
site.
Many enhancers and promoters are being transcribed. nc-
RNA transcription is a major regulatory mechanism of long-
range control elements (33). Recently, novel classes of nc-
RNAs that offer cis- and trans-regulatory potential have been
identified, some of which correlate with the expression state of
protein-coding genes they associate with (32). Analysis of func-
tional elements in 1% of the human genome by the ENCODE
consortium has concluded that the genome is massively tran-
scribed, probably from the multitude of new TSSs identified,
and many new nc-RNAs exist (23). Nevertheless, these studies
do not distinguish between the importance of transcription per
se and the production of functional RNA products. One con-
sequence could be a better binding of transcription factors, as
zinc finger proteins show better binding involving RNA. Inter-
estingly, analysis of publically accessible RNA maps reported
by Kapranov et al. (32). has revealed the existence of a high
density of a new class of nc-RNAs (200 nucleotides, nuclear
and cytosolic polyadenylated) originating from a region ex-
tending between the 11-HSD2 TSS and approximately 2.5 kb
upstream, expressed in all cell lines analyzed (data not shown).
Additionally, the existence of bidirectional expressed sequence
tags overlapping this promoter region can also be found in
databases. Taken together, these data support the observed
capability of this promoter region to generate new nc-RNAs
coexpressed with the 11-HSD2 coding region with potential,
still-not-understood regulatory functions. Detailed analysis of
this region would probably uncover previously unrecognized
TSSs, as has been reported in the ENCODE project (21, 23).
In this vein, several examples of noncoding transcription near
to or overlapping a promoter with major or minor influence on
its activity have been recently reported (26, 35, 40, 61).
RNAP II tracking has been also proposed as a requirement
for activation of the PSA promoter by androgens (66). An
androgen receptor-associated coactivator complex is predom-
inantly recruited to the PSA enhancer, which communicates
with the androgen receptor transcription complex weakly as-
sociated with the PSA promoter through the 4 kb of interven-
ing DNA through which RNAP II tracks. Similarly, integration
of prolactin and glucocorticoid signaling at the -casein pro-
moter involves STAT5A and GR recruitment both to the prox-
imal promoter and to a distal enhancer and RNAP II tracking
(31, 55). Interestingly, STAT5A is recruited to a STAT binding
site and GR acts as a STAT coactivator. Whether RNAP II
tracking generated nc-RNAs was not analyzed. These exam-
ples share striking similarities with the 11-HSD2 model pro-
posed here.
In summary, we describe a mechanism of PR-mediated gene
activation, using the human 11-HSD2 promoter as a model.
Progestin activation of the JAK/STAT pathway and STAT5A-
mediated recruitment of the receptor to a distal enhancer are
essential to recruit active RNAP II that then may track toward
the proximal promoter. The nature and role of the upstream
synthesized nc-RNAs remain to be further investigated.
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